James McCormack

James McCormack

Auto-generated profile, based on publicly available information

James McCormack

Faculty of Pharmaceutical Sciences University of British Columbia Vancouver British Columbia Canada

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1992 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JMJames P. McCormack
James P. McCormack
PJPeter J. Jewesson
Peter J. Jewesson
Routine pharmacokinetic drug monitoring has become an inherent component of aminoglycoside therapy over the last 10–15 years. The intent of this monitoring is to improve the outcome of treatment and to decrease the incidence of toxicity through the attainment and maintenance of serum aminoglycoside concentrations within a normal therapeutic range. The primary objective of this review was to critically analyze the scientific support for the following premises: (1) there is a causal relation between peak serum aminoglycoside concentrations in serum and the out-come of treatment; (2) there is a causal relation between trough serum aminoglycoside concentra-tions in serum and the outcome of treatment; (3) outcome is improved by monitoring and maintenance of serum aminoglycoside concentrations in the normal therapeutic range; (4) there is a causal relation between serum aminoglycoside concentrations and toxicity; and (5) monitoring and maintenance of serum aminoglycoside concentrations within a normal therapeutic range decrease the risk of toxicity. After a critical review of the literature, it was concluded that the evidence was insufficient to support the presently accepted normal therapeutic range. Recommen-dations for the monitoring of aminoglycoside therapy were drawn up.


1 November 1995 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
CMCarolyne J. Montgomery
Carolyne J. Montgomery
JMJames P. McCormack
James P. McCormack
CRClayton C. Reichert
Clayton C. Reichert
CMColin P. Marsland
Colin P. Marsland

1 January 2002
Verified
Journal Article
Closed access
KNKalpana Nair
Kalpana Nair
LDLisa Dolovich
Lisa Dolovich
ACAlan Cassels
Alan Cassels
JMJames McCormack
James McCormack
MLMitch Levine
Mitch Levine
SBSheri Burns
Sheri Burns

30 August 2005 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
JMJames McCormack
James McCormack
KJKevin Johns
Kevin Johns
HTHugh Tildesley
Hugh Tildesley
Metformin has been used for over 40 years for patients with type 2 diabetes mellitus.[1][1] With over 40 million patient-years of use as of 1999,[1][1] there is now evidence that the drug decreases the risk of morbidity and death when used to treat type 2 diabetes.[2][2] However, concern remains

17 December 2014 in BMJ
Verified
Journal Article
Open access
PDF file
CKChristina Korownyk
Christina Korownyk
MKMichael R Kolber
Michael R Kolber
JMJames McCormack
James McCormack
VLVanessa Lam
Vanessa Lam
KOKate Overbo
Kate Overbo
GAG Michael Allan
G Michael Allan
Objective To determine the quality of health recommendations and claims made on popular medical talk shows. Design Prospective observational study. Setting Mainstream television media. Sources Internationally syndicated medical television talk shows that air daily (The Dr Oz Show and The Doctors). Interventions Investigators randomly selected 40 episodes of each of The Dr Oz Show and The Doctors from early 2013 and identified and evaluated all recommendations made on each program. A group of experienced evidence reviewers independently searched for, and evaluated as a team, evidence to support 80 randomly selected recommendations from each show. Main outcomes measures Percentage of recommendations that are supported by evidence as determined by a team of experienced evidence reviewers. Secondary outcomes included topics discussed, the number of recommendations made on the shows, and the types and details of recommendations that were made. Results We could find at least a case study or better evidence to support 54% (95% confidence interval 47% to 62%) of the 160 recommendations (80 from each show). For recommendations in The Dr Oz Show, evidence supported 46%, contradicted 15%, and was not found for 39%. For recommendations in The Doctors, evidence supported 63%, contradicted 14%, and was not found for 24%. Believable or somewhat believable evidence supported 33% of the recommendations on The Dr Oz Show and 53% on The Doctors. On average, The Dr Oz Show had 12 recommendations per episode and The Doctors 11. The most common recommendation category on The Dr Oz Show was dietary advice (39%) and on The Doctors was to consult a healthcare provider (18%). A specific benefit was described for 43% and 41% of the recommendations made on the shows respectively. The magnitude of benefit was described for 17% of the recommendations on The Dr Oz Show and 11% on The Doctors. Disclosure of potential conflicts of interest accompanied 0.4% of recommendations. Conclusions Recommendations made on medical talk shows often lack adequate information on specific benefits or the magnitude of the effects of these benefits. Approximately half of the recommendations have either no evidence or are contradicted by the best available evidence. Potential conflicts of interest are rarely addressed. The public should be skeptical about recommendations made on medical talk shows. Additional details of methods used and changes made to study protocol